KCNH2 and cancer: Considering that hERG1 is closely related to hypoxia and that HIFs remain promising anti-angiogenic agents and direct targets for interfering with the energetics of cancer cells to regulate their growth [91], the possibility of combining hERG channel blockers with drugs targeting hypoxia-related components or developing analogous schemes should be considered in future studies.